Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia

In conclusion, fixed-duration venetoclax + obinutuzumab represents an important chemotherapy-free first-line treatment option for patients with CLL, particularly those who are not fit enough to receive intensive chemoimmunotherapy.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research